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Abstract
Background: It has recently been suggested that the hypergonadotropic hypogonadism 
characterizing Klinefelter syndrome (KS) might not be due to a steroidogenic dysfunction per se, 
but mainly to an altered testosterone (T) secretion into the bloodstream. However, the Leydig 
cell functionality remains incompletely studied in KS, and new markers should be considered. 
Previous data indicated that chronic hCG stimulation influence the production of both Insulin-like 
peptide 3 (INSL3) and 25-hydroxy-vitamin D (25-VD) in eugonadal men. 
Aim of the study: To evaluate INSL3 and 25-VD serum levels, as markers of Leydig cell 
functionality, in association with sex steroids, after an acute hCG test in a group of KS patients 
and healthy volunteers.
Methods: A retrospective analysis of a prospective, case-control, clinical trial was carried out. KS 
patients (n=11) and age-matched healthy controls(n=11) provided a basal blood sample (V0) 
immediately followed by a single intramuscular injection of hCG 5000 IU. Blood samples were 
taken in the following five days(V1-V5). 
Results: At baseline, INSL3 was lower in KS patients compared to controls (p=0.007). When 
adjusted for INSL3 levels, the production of steroids was similar between KS patients and 
controls. 25-VD was in the insufficient range both in KS patients and controls and was not 
different (p=0.064). Acute hCG stimulation increased neither INSL3 nor 25-VD in both KS patients 
and controls. In controls, an inverse correlation was detected between INSL3 levels and body 
mass index (p=0.020) and waist circumference (p=0.020).
Conclusions: INSL3 secretion is independent from steroidogenesis and its production is mostly 
not influenced by acute hCG stimulation both in KS men and controls. INSL3 serum levels should 
be considered as a marker of Leydig cell differentiation and numbers rather than 
steroidogenesis. 25-VD serum levels are also not increased by a single acute hCG administration, 
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Introduction
Klinefelter syndrome (KS) is a clinical condition characterized by chromosome aneuploidy, 
generally 47,XXY, with hypergonadotropic hypogonadism and testicular alterations, such as 
fibrosis accompanied by hyalinization of seminiferous tubules and Leydig cell hyperplasia 1-3. 
Historically, reduced testosterone (T) production has been confirmed by several authors for KS 
men following stimulation with human chorionic gonadotropin (hCG) 4-8. These observations 
have sustained for many years the notion that hypergonadotropic hypogonadism is due to an 
enzymatic defect in testicular steroidogenesis. Recently, this paradigm has been challenged by 
showing that hCG stimulation is able to activate the first steroidogenic steps normally in KS 
Leydig cells, thereby increasing serum T levels as in healthy subjects 9. Thus, the reduced serum T 
levels typical of KS patients are probably not due to a disruption of steroidogenesis but rather to 
a reduced secretion of T from the testis into the circulation 10. With this in mind, the real Leydig 
cell functionality in KS remains unclear. Other testicular hormones and functions should be 
evaluated to understand better Leydig cell functionality in this context 11,12. 
Insulin-like peptide 3 (INSL3) is a member of the relaxin-insulin family of peptide 
hormones and in male mammals is produced by the mature Leydig cells of the testes 13. INSL3 is 
known to have a role in gubernacular differentiation and testicular descent during embryonic 
development 14,15. Its role in adults is less well understood and several authors have suggested 
that INSL3 serum levels could be considered as a serum biomarker of Leydig cell function and a 
peripheral marker of intratesticular T levels 16,17. These hypothetical roles come from the 
demonstration that serum INSL3 drastically declined after chronic gonadotropin deprivation and 
could be partly restored after four days of hCG stimulation in healthy subjects 18. However, in the 
same time-frame, the hCG administration considerably increased serum T levels, rather than 
INSL3, suggesting that INSL3 secretion is independent of T production and not acutely stimulated 
by hCG 18. Thus, INSL3 should probably be considered less as a marker of steroidogenesis and 
intratesticular T, but rather as an indirect marker of Leydig cell functional capacity (Leydig cell 
numbers x differentiation status) 19.
Leydig cell functionality may be further evaluated considering the recently-proposed 
cross-talk between testis and bone. Leydig cells seem able to modulate bone metabolism, 
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the expression of the CYP2R1 gene 21,22. This gene encodes the enzyme involved in 25-
hydroxylation of vitamin D (25-VD), which is a key regulatory factor of bone mineralization and 
calcium homeostasis 21,22. This novel link between testis and bone is further underscored by the 
reduced levels of both INSL3 and 25-VD serum levels 23,24 in hypogonadal patients. However, 
whether VD 25-hydroxylase expression and CYP2R1 transcription in Leydig cells is regulated by 
gonadotropin (hCG) stimulation has so far been poorly investigated, particularly in KS patients . 
Indeed, in vitro and in vivo studies showed that CYP2R1 expression in Leydig cells appeared to be 
hCG dependent 25 and long-term treatment with hCG in hypogonadal men with hypovitaminosis 
D is able to restore 25-VD levels 26.
In this study, we evaluated Leydig cell function in KS patients , considering INSL3 and 25-
VD as new functional markers. In particular, we evaluated the ability of the Leydig cells to 
respond to acute hCG stimulation, comparing KS patients to healthy age-matched controls. 
Materials and Methods
Study design
A retrospective evaluation of a previous, prospective, case-control clinical trial 9 was 
carried out. 
In brief, the study design included six visits. At 8:00 a.m. of the first visit (V0), all subjects 
provided a basal blood sample immediately followed by a single intramuscular injection of hCG, 
5000 IU. During the first visit (V0), the subjects underwent physical examination (height, weight, 
body mass index (BMI), arm span, and upper segment measurement) and testicular ultrasound 
for the calculation of testicular volume. Further visits were performed in the five days following 
hCG injection (V1, V2, V3, V4 and V5). A blood sample was taken at each visit after an overnight 
fast. Blood samples were centrifuged at 3600 rpm for 15 minutes. Sera were transferred into 
plain polypropylene tubes and stored at -20°C until assayed. 
Thirteen KS patients and 12 age-matched, healthy control subjects were enrolled in the 
original study. Of these patients, blood samples were available for INSL3 and 25-VD 
measurements in 11 KS patients and 11 controls. For this retrospective analysis not all samples 
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Inclusion criteria for the KS patients were: (i) genetic diagnosis of KS by karyotype analysis 
showing non mosaic 47,XXY karyotype on 50 metaphases, (ii) age between 18 and 45 years, and 
(iii) no current or past androgen replacement therapy (naïve KS patients). Inclusion criteria for 
the control group were: (i) 46,XY karyotype, (ii) normal testosterone and gonadotropin serum 
levels, (iii) age between 18 and 45 years, and (iv) no history of pubertal delay, chronic disease 
and absence of risk factors for testicular dysfunction.
Hormonal evaluation
INSL3 serum levels were measured by a well validated time-resolved fluorescent 
immunoassay 13.
Progesterone, 17-hydroxy-progesterone (17-OHP), Androstenedione, 
dehydroepiandrosterone (DHEA), and T were determined by liquid chromatography, tandem 
mass spectrometry (LC–MS/MS) at the laboratory of the Centre for Applied Biomedical Research 
of the S. Orsola-Malpighi Hospital, Alma Mater Studiorum, University of Bologna, Bologna, Italy, 
as previously reported 9. 
Finally, 25-VD was measured by a chemiluminescent immunoassay on a fully automated 
platform (LIAISON XL 25 Dihydroxyvitamin D, DiaSorin S.p.A Italy). The assay was performed in 
the laboratory of endocrinology, belonging to the Department of Laboratory Medicine and 
Pathology, AUSL Modena.
Statistical analysis
Data are shown as means and standard deviation. Data distribution was evaluated by 
Kolmogorov-Smirnov test. First, to better understand the trending profile of INSL3 after hCG 
stimulation and to confirm its constitutive production, V1 and V2 data were also pooled 
together, as well as V4 and V5, reducing the data variance, since the dynamics of any INSL3 
increase are not known. Moreover, data were expressed as percentage variation relative to 
baseline (V0) levels. Then, the comparison between KS patients and controls was performed 
considering patients at baseline (V0). The T on INSL3 ratio (T/INSL3) and 17-OHP on INSL3 ratio 
(17-OHP/INSL3/) were also calculated using INSL3 values to correct for possible variations in 
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ANOVA univariate and Mann-Whitney U test were used for normally and not-normally 
distributed parameters, respectively. The INSL3 and 25-VD response to hCG stimulation was 
evaluated comparing data among visits using the Kruskal-Wallis test. The Tukey test was used to 
perform post hoc analyses. Moreover, INSL3 serum levels were compared between KS patients 
and controls at each visit, using ANOVA univariate or Mann-Whitney U test for normally and not-
normally distributed parameters, respectively. The correlation between INSL3 and other 
parameters collected were evaluated by Pearson and Rho’s Spearman correlation tests, for 
normally and not-normally distributed parameters, respectively.
Statistical analysis was performed using the ‘Statistical Package for the Social Sciences’ 
software for Windows (version 21.0; SPSS). For all comparisons, p-values of <0.05 were 
considered to be statistically significant.
Results 
Baseline Leydig cell functionality
The steroid profiles after hCG stimulation in KS patients and controls have been 
previously published 9,27. 
On average, baseline INSL3 levels (V0) were lower in KS patients (444 + 350 pg/mL) than 
in controls (780 + 190 pg/mL) (p=0.007) (Table 1). 
T serum levels were significantly lower in KS patients compared to controls (9.35 + 3.34 vs 
15.16 + 4.77 nmol/L, p=0.004), whereas 17-OHP serum levels were not significantly different 
between KS patients and controls (2.97 + 0.80 vs 4.68 + 2.59 nmol/L, p=0.052). When Leydig cell 
steroid production was adjusted for INSL3 levels, as a measure of the number and differentiation 
status of the Leydig cells, the T/INSL3 and 17-OHP/INSL3 ratios were not significantly different 
between KS patients and controls (p=0.251 and p=0.282, respectively). This result suggests that 
the Leydig cell steroidogenic potential is preserved in this genetic syndrome.
At baseline, 25-VD serum levels were not significantly different between KS patients and 
controls (22.76 + 5.84 vs 17.14 + 6.84 ng/mL, p=0.064), although below the normal ranges (i.e. 
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In KS patients , basal INSL3 levels did not significantly correlate with serum T levels (Rho 
0.575, p=0.064). Moreover, no correlations were found between INSL3 and 17-OHP (Rho 0.409, 
p=0.212), androstenedione (Rho 0.238, p=0.482) and 25-VD (Rho 0.118, p=0.729). However, 
although the KS patients’ testes were small, INSL3 significantly correlated with testicular volume 
(Figure 1), but not with patients’ age or anthropometric parameters. Basal 25-VD serum levels 
were not related to T (Rho -0.218, p=0.519), 17-OHP (Rho -0.155, p=0.650), androstenedione 
(Rho -0.173, p=0.612), testicular volume, patients’ age, or anthropometric parameters.
In controls, INSL3 was inversely related to BMI (Rho -0.750, p=0.020) and waist 
circumference (Rho -0.750, p=0.020), while no significant correlations were found between INSL3 
and serum testosterone (Rho 0.202, p=0.663), 17-OHP (Rho -0.550, p=0.125), androstenedione 
(Rho 0.171, p=0.660), or 25-VD (Rho 0.588, p=0.074). Moreover, no correlations were found 
among INSL3 and testicular volume, controls’ age and other anthropometric measures. Similarly, 
basal 25-VD did not correlate with T (Rho -0.079, p=0.829), 17-OHP (Rho -0.212, p=0.556), 
androstenedione (Rho -0.248, p=0.249), testicular volume, controls’ age or anthropometric 
parameters.
Human chorionic gonadotropin (hCG) stimulation
HCG stimulation did not significantly change INSL3 and 25-VD serum levels, neither in KS 
patients nor in controls (Table 1). Interestingly, the INSL3 variation after hCG administration is 
heterogeneous among patients in both groups (Figure 2). To confirm the constitutive pattern of 
INSL3 production, the secretion pattern was compared between INSL3 and 17-OHP (Figure 3). 
When the data were pooled across subjects for V1 and V2 as well as for V4 and V5, there was no 
significant effect of hCG stimulation on INSL3 for either controls or KS patients (Figure 3). These 
results suggest that hCG stimulation rapidly increases 17-OHP serum levels and, consequently, T, 
without changes in INSL3 serum levels. However, a small INSL3 increase at V1 and V2 upon hCG 
stimulation was observed in two KS patients and four controls (Figure 2). Taken together, these 
results confirm that INSL3 production and secretion are acutely independent from 
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Considering each visit, INSL3 remained significantly higher in controls compared to KS 
patients at V1, V4 and V5 (Table 1). On the other hand, INSL3 serum levels were similar between 
KS patients and controls at V2 and V3 (Table1). Similarly, both T/INSL3 and 17-OHP/INSL3 ratios 
remained similar between KS patients and controls at each visit (data not shown). Finally, 25-VD 
did not differ between KS patients and controls at any visit.
Discussion
Here, we confirm that KS patients’ Leydig cells on average secrete INSL3 into the blood 
circulation at a slightly reduced rate compared to healthy subjects 29. On average, INSL3 serum 
levels are 45% lower than in healthy age-matched controls 29,30, in line with previous reports 23,24. 
In our small group of patients , we first confirm that INSL3 production is independent from 
steroidogenesis and is constitutively represented. Interestingly, although the average INSL3 
serum levels are lower in KS patients than controls, a high variability is observed, and some KS 
patients have INSL3 serum levels within the reference range. Indeed, also T levels in KS patients 
are normal in about 50% of cases, although the mean values are lower than normal. Acute hCG 
stimulation is not able to increase the INSL3 production rate, which remains stable and is 
probably related to cell differentiation status and number. 
Here, we confirm low T serum levels in KS patients , as previously reported 1,31. However, 
the old paradigm of low T levels in KS men due to steroidogenic dysfunction has been recently 
changed. In 2010, an experimental mouse model of KS (41,XXY) was generated, showing 
hyperplastic Leydig cells hyper-reactive to hCG in vitro, with intratesticular T levels comparable 
to wild type mice 32-34. In 2014, high intratesticular T levels were demonstrated for the first time 
in KS men, despite reduced serum T levels 10. Accordingly, in 2016, we demonstrated that 
steroidogenesis starts normally in KS patients after acute hCG stimulation 9. This evidence 
suggests that Leydig cell function, at least in regard to steroidogenesis, is not impaired in KS and 
that the low T levels detected in the blood could be due to lower T release into the blood 
circulation 10. Here, we have not evaluated intratesticular T, thus we could not speculate on the 
real T production in KS patients . However, we show a constitutive INSL3 production, 
independent from steroidogenesis and acute hCG stimulation and probably reflecting the Leydig 
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Leydig cell functional capacity (i.e. INSL3 serum levels), no differences are detected between KS 
patients and controls, confirming that the Leydig cell capability is preserved in KS patients.
Several authors have evaluated INSL3 serum levels after chronic hCG stimulation. First, 
when gonadotropic suppression is achieved in eugonadal men by GnRH agonist 37 or antagonist 
17 administration, the Leydig cell activity is impaired, with a consequent reduction in INSL3 and T 
levels 38-40. Then chronic Leydig cell stimulation with endogenous gonadotropins leads to 
inhibition of the hypothalamic-pituitary-gonadal axis, with a consequent Leydig cell de-
differentiation and INSL3 reduction 38-40. Second, other authors suggested that chronic hCG 
stimulation could elicit INSL3 serum increase by inducing a further differentiation of less 
immature Leydig cells 30. Here, we have evaluated an acute hCG stimulation that should not 
affect the Leydig cell differentiation state and thus should not be reflected in a change of INSL3 
serum level. HCG acute administration activates a specific signal transduction pathway, which 
acutely stimulates steroidogenesis but not INSL3 production 30. It is well known that hCG 
activates signal transduction pathways partly different from LH, although they act on the same 
membrane receptor (LHCGR) 41,42. In particular, hCG mainly leads to intracellular cyclic adenosine 
mono-phosphate (cAMP) increase, which in turns acutely stimulates T production 41,42. On the 
other hand, less is known about the transcriptional pathways at the basis of INSL3 production, 
and only few transcription factors have been found to regulate Insl3 promoter in vitro, such as 
NUR77, KLF6, COUP-TFII and SF1 43-45. HCG stimulation of the murine MA-10 Leydig cell line in 
vitro resulted in a transient robust increase in Nur77 mRNA, which, however, does not lead to 
INSL3 intracellular mRNA increase 46. Other reports indeed showed that cAMP is involved in 
INSL3 production from the MA-10 Leydig cells through interaction with another transcription 
factor, NR4A1 45. Nevertheless, it is now accepted that the acute hCG stimulation of the LHCGR 
does not regulate INSL3 production, which, in contrast, is constitutively regulated in Leydig cells 
depending on their differentiation and maturity.
In our small group of healthy subjects, INSL3 is not related to T serum levels, but only to 
anthropometric variables, such as BMI and waist circumference. Previous reports showed 
negative correlation between INSL3 levels and BMI in obese men, suggesting that obesity might 
alter the functionality of the Leydig cells 47. These data have been also confirmed in obese 
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men with type 2 diabetes mellitus, waist circumference negatively correlates with INSL3 49, again 
suggesting an overall Leydig cell dysfunction caused by visceral adiposity. Furthermore, Overvad 
and colleagues demonstrated a negative correlation between INSL3 and metabolic parameters in 
healthy men, such as serum glucose levels and the homeostasis model assessment (HOMA) index 
29. Therefore, anthropometric parameters could influence global Leydig cell function (INSL3 and T 
production). However, this is not true in our KS patients, where anthropometric characteristics 
are probably influenced more by the genetics-related phenotype and by the longstanding 
untreated hypogonadism. Although there is no evident relationship between testis size and 
INSL3 production in control subjects, there is indeed a significant correlation between these two 
parameters in KS patients. The small average size of the testes in KS patients, in spite of near 
normal INSL3 levels, emphasizes that the condition predominantly affects the seminiferous 
compartment, thereby explaining why the proportionately larger interstitial compartment can 
correlate with overall testis size in KS patients but not in controls. Considering that the Leydig 
cells of several KS patients were secreting INSL3 in the normal range, this strongly suggests that 
the chromosomal abnormality of KS patients is influencing the interstitial compartment far less 
than the seminiferous compartment, at least for some KS patients. Indeed, the testicular damage 
in KS starts in general from mid-puberty, and it involves both compartments, as evidenced by 
increased levels of FSH and LH invariably in all KS patients. However, the extent of this damage is 
variable among KS patients and we can speculate that the Leydig cell differentiation that 
normally occur during puberty could proceed variably among KS patients, therefore determining 
different INSL3 levels in adults as marker of the Leydig cell global activity and maturity.
We confirmed here that KS patients have low-normal 25-VD serum levels, similarly to 
healthy subjects who also had subnormal values. Both in mouse models and humans, the 25-
hydroxilating enzyme CYP2R1 mRNA is expressed in many tissues, with the highest relative 
expression in the testis 50,51. Moreover, several authors have suggested a reduced vitamin D 
activation in patients with testiculopathy 20,52. These demonstrations led to the interesting 
suggestion that 25-VD serum levels could be altered in KS men and related to bone mineral 
density and risk of osteoporosis 53. Here, the number of patients enrolled is limited, aiming at 
describing only the effects of hCG stimulation on 25-VD levels. Moreover, it was suggested that 









This article is protected by copyright. All rights reserved
hypogonadotropic hypogonadism 25,26,50,54,55. Here, 25-VD serum levels do not increase after 
acute hCG administration, suggesting that the acute LHCGR activation in vivo is not able to 
stimulate testicular CYP2R1 expression and VD 25-hydroxylation. However, these results should 
be cautiously evaluated, considering the small sample size in both groups and the reduced 25-VD 
serum levels detected at baseline in both KS patients and controls. 
Our study shows important limitations. First, this is a retrospective analysis that should be 
cautiously evaluated. Second, the sample size is limited, although it is in line with the KS 
prevalence. Third, we are not able to clearly evaluate Leydig cell functionality, since 
intratesticular T measurement was not available. Fourth, 25-VD serum levels vary among and 
within subjects, and were low in all subjects, including controls. Finally, this study was not 
designed to evaluate the usefulness of INSL3 measurement in clinical practice. Indeed, currently 
due to methodological limitations the measurement of INSL3 does not find a clear clinical 
application in KS men, and future studies are needed.
In conclusion, this study demonstrates that INSL3 secretion is independent from 
steroidogenesis and its production seems to be not influenced by acute hCG stimulation both in 
KS men and controls. Although INSL3 serum levels should be considered as a marker of Leydig 
cell differentiation and numbers, its implication in clinical practice should be further analyzed 
with well-designed clinical trials.
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Table 1.
INSL3 (pg/mL) KS patients controls p-value
Visit 0 440 + 350 780 + 190 0.007
Visit 1 520 + 320 830 + 190 0.024
Visit 2 580 + 340 790 + 290 0.133
Visit 3 460 + 340 760 + 320 0.079
Visit 4 410 + 250 780 + 310 0.010
Visit 5 300 + 230 720 + 260 0.002
p-value 0.447 0.951
25-VD (ng/mL)
Visit 0 22.68 + 6.98 17.14 + 6.84 0.101
Visit 1 22.97 + 5.45 16.83 + 6.73 0.060
Visit 2 22.31 + 4.06 16.92 + 6.34 0.056
Visit 3 21.85 + 4.70 17.03 + 6.62 0.076
Visit 4 21.66 + 4.48 17.27 + 6.73 0.076
Visit 5 22.04 + 4.89 16.98 + 6.12 0.056
p-value 0.999 0.999
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Figure legend
Figure 1. Linear regression between basal INSL3 and testicular volume in KS men.
[Footnotes to Figure 1]: INSL3: Insulin like peptide 3, KS: Klinefelter syndrome.
Figure 2. INSL3 serum levels at each visit in KS men (panel A) and controls (panel B). Gaps in the 
histograms represent missing samples
[Footnotes to Figure 2]: INSL3: Insulin like peptide 3, KS: Klinefelter syndrome.
Figure 3. INSL3 and 17-OHP serum levels after hCG stimulation, aggregating V1 with V2, and V4 
with V5 in KS men (panel A) and controls (panel B).
[Footnotes to Figure 2]: 17-OHP: 17-hydroxy-progesterone, avg: average, INSL3: Insulin like 
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